12th Jun 2026 11:30
(Alliance News) - The following are the leading risers and fallers among London Main Market small-cap and AIM stocks on Friday.
----------
Main Market small-cap winners
----------
Alkemy Capital Investments PLC, up 34% at 303.00 pence
Octopus AIM VCT 2 PLC, up 20% at 30.00p
Unicorn Mineral Resources PLC, up 15% at 7.50p
capAI PLC, up 9.6% at 0.74p
Cizzle Biotechnology Holdings PLC, up 9.1% at 3.00p, wins US patent for lung cancer biomarker measures
----------
Main Market small-cap losers
----------
BSF Enterprise PLC, down 38% at 1.25p, says T-Rex leather handbag fails to achieve reserve price at auction
McBride PLC, down 11% at 147.70p, flags Middle East cost impacts
Nuformix PLC, down 10% at 0.18p
ICG-Longbow Senior Secured UK Property Debt Investments Ltd, down 7.0% at 12.55p
Tullow Oil PLC, down 6.3% at 14.49p, oil stocks fall on peace deal hopes
----------
AIM winners
----------
MedPal AI PLC, up 24% at 3.85p, expects benefit from UK approval of Wegovy pill
SkinBioTherapeutics PLC, up 23% at 8.00p
Futura Medical PLC, up 21% at 0.66p
Finseta PLC, up 14% at 9.25p
CML Microsystems PLC, up 12% at 297.50p
----------
AIM losers
----------
Pri0r1ty Intelligence Group PLC, down 50% at 0.85p, reports wider loss
Tanfield Group PLC, down 16% at 4.61p
Virgin Wines UK PLC, down 15% at 28.50p, cuts full-year earnings guidance
UK Oil & Gas PLC, down 10% at 0.00875p, sells Horse Hill oil field interest
Mercantile Ports & Logistics Ltd, down 9.7% at 1.40p
----------
Small-cap and AIM movers in focus:
----------
Cizzle Biotechnology Holdings PLC, up 9.1% at 3.00p, 12-month range 1.20p-3.90p. The London-based life sciences company secures a US patent for its core methods to measure the CIZ1B lung cancer biomarker. The test format is licensed to Cizzle Bio Inc for use in North America and the Caribbean.
----------
BSF Enterprise PLC, down 38% at 1.25p, 12-month range 0.50p-4.00p. The London-based biotechnology investment group, which focuses on lab-grown meat and leather, says its T-Rex leather handbag failed to achieve its reserve price at an auction in Paris. The firm says bidding for the "unique, museum-grade luxury handbag" topped out at EUR150,000. As a result, the handbag has been withdrawn from auction and is being prepared for sale to a high-net-worth buyer.
----------
McBride PLC, down 11% at 147.70p, 12-month range 106.20-170.00p. The Manchester, England-based private-label products manufacturer reports sustained cost increases in petrochemical-derived and energy-intensive materials due to the Middle East conflict. The company says the cumulative impact on input costs exceeds its original expectations. "Whilst the duration of this conflict remains uncertain, at this stage we are of the view that direct cost pressures are unlikely to either rise considerably further or experience meaningful near-term decline," it says. McBride expects its performance to normalise and be back on track with previous expectations for the second quarter of the financial year to June 2027 and beyond. It expects financial 2026 and 2027 adjusted earnings before interest, tax and amortisation to be between 5% and 10% lower than current analyst expectations. The current consensus is for adjusted Ebitda of GBP64.2 million for financial 2026 and GBP70.6 million for financial 2027. McBride expects to complete the acquisition of Eurotab at the start of July.
----------
MedPal AI PLC, up 24% at 3.85p, 12-month range 2.00p-13.50p. The London-based digital health and AI company says the UK approval of Novo Nordisk AS's Wegovy pill is "directly relevant" to its weight management clinic, New Health. The company says the tablet is not currently available on the NHS, meaning private provision is the only route to access. The firm says it considers US demand for the same product earlier this year to be an "instructive leading indicator" of likely UK demand. US prescriptions for the tablet surpassed three million in just over five months. The company says it believes its vertically integrated model positions New Health to respond to anticipated patient demand in the UK.
----------
Virgin Wines UK PLC, down 15% at 28.50p, 12-month range 24.00p-80.50p. The Norwich, England-based online wine retailer cuts its guidance and says the war in the Middle East continues to pressure consumer confidence and discretionary spend. The firm says it signs a lease for a new warehouse facility in Preston, England. Virgin Wines says it continues to win market share and expects to achieve around 4% revenue growth in financial 2026 to July 3. The firm now expects financial 2026 revenue of around GBP61 million, earnings before interest, tax, depreciation and amortisation of negative GBP200,000 and a pretax loss of GBP1.5 million. Current market exepectations were for revenue of GBP63.3 million, Ebitda of GBP100,000 and a pretax loss of GBP1 million. Chief Executive Officer Jay Wright says: "Our execution against the key pillars of our growth strategy is delivering encouraging progress, despite that growth now being slightly slower than our original plan due to external market pressures."
----------
By Michael Hennessey, Alliance News reporter
Comments and questions to [email protected]
Copyright 2026 Alliance News Ltd. All Rights Reserved.
Related Shares:
Alkemy Capital.Octopus Aim 2Unicorn Mineral ResourcesCapaiCizzle BiotechBio-Sustainable Future EnterprisesMcbrideNuformixIcg-longbowTullow OilMedpal AISkinbiotherap.Futura MedicalFinsetaCML MicrocircuitsPri0r1ty IntTanfieldVirgin WinesUK Oil & GasMercantile Ports & Logistics